- March 31, 2008 at 11:00 a.m. EDT
NEW YORK and HAIKOU CITY, China, March 26 /Xinhua-PRNewswire-FirstCall/ -- China Pharma Holdings, Inc. ("China Pharma") (OTC Bulletin Board: CPHI) which develops, manufactures, and markets generic and branded bio-pharmaceutical products in China, today announced it will release its Fourth Quarter and Year End 2007 results on Monday 31, 2008. In conjunction, the Company will host an earnings conference call to discuss these results.
Ms. Zhilin Li, President and CEO of China Pharma Holdings, Inc., Mr. Xinhua Wu, Chief Financial Officer, and Mr. Alan Sheinwald, Partner of HC International will be joining the call.
The earnings conference call will take place at 11:00 a.m. EDT on Monday, March 31, 2008. To participate in the conference call, please dial 1-800-762-8908 ten minutes prior to the scheduled conference call time. International callers should dial 1-480-629-9041. The conference ID is 3862567.
This conference call will be broadcast live over the Internet and can be accessed by clicking this link: http://www.wsw.com/webcast/cc/cphi/ . For those unable to participate during the live broadcast, a replay will be available shortly after the call on China Pharma's website http://www.chinapharmaholdings.com for 90 days.
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. develops, manufactures, and markets generic and brand bio-pharmaceutical products in China that treat a wide range of conditions, including infections, hepatitis, cardiovascular and CNS diseases, and other prevailing diseases. Helpson Bio-pharmaceutical Co., Ltd (Helpson), a specialty pharmaceutical company headquartered in Haikou City, Hainan province in China, is a wholly owned subsidiary of China Pharma Holdings. For more information about China Pharma Holdings, Inc., please visit http://www.chinapharmaholdings.com .
Safe Harbor Statement:
Certain statements in this press release and oral statements made by
China Pharma on its conference call in relation to this release, constitute
forward- looking statements for purposes of the safe harbor provisions
under The Private Securities Litigation Reform Act of 1995. Any statements
set forth above that are not historical facts are forward-looking
statements that involve risks and uncertainties that could cause actual
results to differ materially from those in the forward-looking statements,
which may include, but are not limited to, such factors as unanticipated
changes in product demand, increased competition, failure to obtain or
maintain intellectual property protection, downturns in the Chinese
economy, uncompetitive levels of research and development, failure to
obtain regulatory approvals, and other information detailed from time to
time in the Company's filings and future filings with the United States
Securities and Exchange Commission. The forward-looking statements made
herein speak only as of the date of this press release and the Company
undertakes no duty to update any forward-looking statement to conform the
statement to actual results or changes in the company's expectations.
For more information, please contact:
China Pharma Holdings, Inc.
HC International, Inc.
|SOURCE China Pharma Holdings, Inc.|
Copyright©2008 PR Newswire.
All rights reserved